AX-2025-020826

GHRP-6 · 10 mg declared · Sangon Biotech (Shanghai) Co., Ltd. · lot SGN-2504-X1136

FAILVERIFIED

Report ID: AX-2025-020826
Compound: GHRP-6
Compound class: Growth-hormone axis peptides
Supplier: SGN — Sangon Biotech (Shanghai) Co., Ltd.
Batch / lot: SGN-2504-X1136
Declared label claim: 10mg
Laboratory: Janoshik Analytical
Assay date: 10 Aug 2025
Submitted: 19 Aug 2025
Quarter: 2025-Q3
Submitter: d.restrepo
Sample provenance: Laboratory-retained

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.47	% area	≥ 99.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.53	% area	≤ 1.0	FAIL
Largest single impurity	RP-HPLC — oxidised Trp (+16 Da)	0.72	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	872.4446	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	872.4395	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-5.8	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	3.77	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.53	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.42	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.34	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Faint haze, clearing on standing	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.96	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	8.44	min	8.44 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.01	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	42,330	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.71	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 42,330, and skew follows the reported asymmetry factor of 1.01. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.72 % impurity against a 98.47 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-6 — main peak	8.44	4,785,947	98.47	—
2	oxidised Trp (+16 Da)	8.10	34,994	0.72	+15.995
3	[D-Trp]-epimer	8.32	27,218	0.56	0.000
4	des-Lys (−128 Da)	8.22	6,804	0.14	-128.095
5	bis-oxidised Trp (+32 Da)	7.86	5,346	0.11	+31.990
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 872.4446 Da, computed from C46H56N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 872.4395 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	437.2296	437.2270	-0.0026	54.8
1+	873.4519	873.4468	-0.0051	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.79	98.47	divergence +0.17 pp vs batch median
Total impurities (% area)	1.21	1.53
Largest single impurity (% area)	not stated	0.72
Water (%)	not stated	3.77
Counter-ion (%)	not stated	5.53
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	0.34
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 29 d since original receipt) → re-assay.
Assay date: 10 Aug 2025
Submitted to the index: 19 Aug 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot SGN-2504-X1136 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020824	SGN-2504-X1136	Medutest	2025-Q3	99.54	3.75	—	Supplier-supplied	1	FAIL
AX-2025-020825	SGN-2504-X1136	Janoshik	2025-Q3	98.48	4.48	—	Buyer-sourced	1	FAIL
AX-2025-020827	SGN-2504-X1136	Janoshik	2025-Q3	98.62	3.52	106.7	Supplier-supplied	1	FAIL
AX-2025-020828	SGN-2504-X1136	Medutest	2025-Q3	98.79	3.97	93.2	Buyer-sourced	2	FAIL
AX-2025-020829	SGN-2504-X1136	Janoshik	2025-Q3	98.80	3.38	106.2	Supplier-supplied	1	FAIL
AX-2025-020830	SGN-2504-X1136	PeptideMeter	2025-Q3	98.45	4.24	98.1	Laboratory-retained	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-6 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042290	HJ	HJ-2603-R2258	Janoshik	2026-Q3	99.71	3.05	—	Supplier-supplied	2	MARGINAL
AX-2026-042287	HJ	HJ-2603-R2258	VendorInvestigate	2026-Q3	98.79	2.43	90.9	Buyer-sourced	2	FAIL
AX-2026-042288	HJ	HJ-2603-R2258	Kestrel	2026-Q3	99.93	2.82	92.8	Supplier-supplied	2	MARGINAL
AX-2026-042289	HJ	HJ-2603-R2258	Janoshik	2026-Q3	99.53	2.67	104.7	Supplier-supplied	2	MARGINAL
AX-2026-042291	HJ	HJ-2603-R2258	Janoshik	2026-Q3	99.60	2.94	101.3	Supplier-supplied	2	MARGINAL
AX-2026-043560	BCH	BCH-2603-Y7018	Janoshik	2026-Q2	99.25	5.25	—	Supplier-supplied	1	MARGINAL
AX-2026-043564	BCH	BCH-2603-Y7018	Medutest	2026-Q2	98.44	4.83	—	Buyer-sourced	1	FAIL
AX-2026-043562	BCH	BCH-2603-Y7018	PeptideMeter	2026-Q2	98.57	4.52	97.9	Supplier-supplied	1	FAIL

Other recent SGN records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043215	Afamelanotide	SGN-2602-Y9898	PeptideMeter	2026-Q3	98.92	3.40	—	Supplier-supplied	1	MARGINAL
AX-2026-043214	Afamelanotide	SGN-2602-Y9898	Janoshik	2026-Q3	99.19	3.41	106.9	Supplier-supplied	1	MARGINAL
AX-2026-043240	Melanotan II	SGN-2602-L1809	PeptideMeter	2026-Q2	98.65	2.87	—	Supplier-supplied	2	MARGINAL
AX-2026-043255	BPC-157	SGN-2512-H1950	Janoshik	2026-Q2	99.06	4.99	—	Supplier-supplied	2	MARGINAL
AX-2026-043242	Melanotan II	SGN-2602-L1809	VendorInvestigate	2026-Q2	98.14	2.18	107.2	Buyer-sourced	1	FAIL
AX-2026-043221	SLU-PP-332	SGN-2602-X9969	Kestrel	2026-Q2	98.70	5.87	—	Supplier-supplied	0	PASS
AX-2026-043245	Melanotan II	SGN-2602-L1809	Janoshik	2026-Q2	98.54	2.19	100.6	Supplier-supplied	2	MARGINAL
AX-2026-043244	Melanotan II	SGN-2602-L1809	Janoshik	2026-Q2	99.24	2.68	98.0	Supplier-supplied	1	MARGINAL